Compare Pfizer Inc (PFE) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Tesla, Inc. — how do they compare? Pfizer Inc trades at $27.74 (market cap $159.59B), while Tesla, Inc. trades at $379.54 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 9.3× Pfizer Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Tesla, Inc. for 88 Days on average.
| PFE | TSLA | |
|---|---|---|
Market Cap | $159.59B | $1.49T |
Volume | 30,937,010 | 25,496,215 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $489.88 |
52-Week Low | $23.67 | $298.16 |
Typical Hold Time | 158 Days | 88 Days |
Enterprise Value | $211.09B | $1.46T |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Tesla (TSLA) trades at $375.03, down 1.48% with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs $0.50 expected) following two previous beats, with revenue declining to $94.83B in 2025. Analyst sentiment remains divided with 41% buy ratings but a consensus price target of $441.36 suggesting 18% upside. Recent regulatory approval for driver-assistance software in Europe provides near-term catalyst potential.
Tesla faces execution risks amid slowing auto growth but maintains leadership in autonomous driving technology. The stock's premium valuation (P/E 349.82) requires successful expansion into robotics and AI to justify current levels. Near-term pressure from delivery misses contrasts with long-term potential in energy and autonomy markets, creating a high-risk, high-reward investment profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
